Review



surrogate viral neutralization test genscript cpass sars-cov-2 neutralization antibody test  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation surrogate viral neutralization test genscript cpass sars-cov-2 neutralization antibody test
    Surrogate Viral Neutralization Test Genscript Cpass Sars Cov 2 Neutralization Antibody Test, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/surrogate viral neutralization test genscript cpass sars-cov-2 neutralization antibody test/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    surrogate viral neutralization test genscript cpass sars-cov-2 neutralization antibody test - by Bioz Stars, 2026-06
    90/100 stars

    Images



    Similar Products

    surrogate viral neutralization test genscript cpass sars-cov-2 neutralization antibody test  (GenScript corporation)
    90
    GenScript corporation surrogate viral neutralization test genscript cpass sars-cov-2 neutralization antibody test
    Surrogate Viral Neutralization Test Genscript Cpass Sars Cov 2 Neutralization Antibody Test, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/surrogate viral neutralization test genscript cpass sars-cov-2 neutralization antibody test/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    surrogate viral neutralization test genscript cpass sars-cov-2 neutralization antibody test - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    surrogate neutralizing antibody test genscript cpass  (GenScript corporation)
    90
    GenScript corporation surrogate neutralizing antibody test genscript cpass
    Surrogate Neutralizing Antibody Test Genscript Cpass, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/surrogate neutralizing antibody test genscript cpass/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    surrogate neutralizing antibody test genscript cpass - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    sars-cov-2 surrogate virus neutralization test (svnt) by genscript cpass tm sars-cov-2 neutralization antibody detection kit  (GenScript corporation)
    90
    GenScript corporation sars-cov-2 surrogate virus neutralization test (svnt) by genscript cpass tm sars-cov-2 neutralization antibody detection kit
    Sars Cov 2 Surrogate Virus Neutralization Test (Svnt) By Genscript Cpass Tm Sars Cov 2 Neutralization Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars-cov-2 surrogate virus neutralization test (svnt) by genscript cpass tm sars-cov-2 neutralization antibody detection kit/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    sars-cov-2 surrogate virus neutralization test (svnt) by genscript cpass tm sars-cov-2 neutralization antibody detection kit - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    surrogate virus neutralization test genscript cpass sars-cov-2 neutralization antibody detection  (GenScript corporation)
    90
    GenScript corporation surrogate virus neutralization test genscript cpass sars-cov-2 neutralization antibody detection
    Longitudinal measurements of neutralizing antibodies in different groups of severity. Lineplot representing inhibition percentage kinetics of neutralizing antibodies through four longitudinal measurements. Each point represents the median <t>neutralization</t> value with standard error for that follow-up. The non-hospitalized group is represented by the orange line, the blue line represents recovered hospitalized patients, and the purple line represents deceased hospitalized patients.
    Surrogate Virus Neutralization Test Genscript Cpass Sars Cov 2 Neutralization Antibody Detection, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/surrogate virus neutralization test genscript cpass sars-cov-2 neutralization antibody detection/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    surrogate virus neutralization test genscript cpass sars-cov-2 neutralization antibody detection - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Longitudinal measurements of neutralizing antibodies in different groups of severity. Lineplot representing inhibition percentage kinetics of neutralizing antibodies through four longitudinal measurements. Each point represents the median neutralization value with standard error for that follow-up. The non-hospitalized group is represented by the orange line, the blue line represents recovered hospitalized patients, and the purple line represents deceased hospitalized patients.

    Journal: Vaccines

    Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

    doi: 10.3390/vaccines10122063

    Figure Lengend Snippet: Longitudinal measurements of neutralizing antibodies in different groups of severity. Lineplot representing inhibition percentage kinetics of neutralizing antibodies through four longitudinal measurements. Each point represents the median neutralization value with standard error for that follow-up. The non-hospitalized group is represented by the orange line, the blue line represents recovered hospitalized patients, and the purple line represents deceased hospitalized patients.

    Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

    Techniques: Inhibition, Neutralization

    Longitudinal measurements of total anti-N antibodies in different groups of severity. Lineplot representing total anti-N antibody concentration through four longitudinal measurements. Each point represents the median neutralization value with standard error for that follow-up. The non-hospitalized patients group is represented by the orange line, the blue line represents recovered hospitalized patients, and the purple line represents deceased hospitalized patients.

    Journal: Vaccines

    Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

    doi: 10.3390/vaccines10122063

    Figure Lengend Snippet: Longitudinal measurements of total anti-N antibodies in different groups of severity. Lineplot representing total anti-N antibody concentration through four longitudinal measurements. Each point represents the median neutralization value with standard error for that follow-up. The non-hospitalized patients group is represented by the orange line, the blue line represents recovered hospitalized patients, and the purple line represents deceased hospitalized patients.

    Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

    Techniques: Concentration Assay, Neutralization

    Proportion of patients in each neutralization category. Barplots show the proportion of patients with the different antibody classifications in each follow-up and within study groups (non-hospitalized, recovered, and deceased). Neutralization categories: 0–30% negative production, 31–60% low production, 61–90% medium production, and >90% high production. Initial measurement stands for the first follow-up measurement in a period of <14 days post-symptom onset, follow-up 1 for the period between 14 and 21 days post-symptom onset, follow-up 2 for the period between 22 and 30 days post-symptom onset, and follow-up 3 for the last measurement 30 days post-symptom onset. * = p < 0.05, *** = p < 0.0001.

    Journal: Vaccines

    Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

    doi: 10.3390/vaccines10122063

    Figure Lengend Snippet: Proportion of patients in each neutralization category. Barplots show the proportion of patients with the different antibody classifications in each follow-up and within study groups (non-hospitalized, recovered, and deceased). Neutralization categories: 0–30% negative production, 31–60% low production, 61–90% medium production, and >90% high production. Initial measurement stands for the first follow-up measurement in a period of <14 days post-symptom onset, follow-up 1 for the period between 14 and 21 days post-symptom onset, follow-up 2 for the period between 22 and 30 days post-symptom onset, and follow-up 3 for the last measurement 30 days post-symptom onset. * = p < 0.05, *** = p < 0.0001.

    Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

    Techniques: Neutralization

    ( A , B ). Antibody titers and survival analysis. Kaplan–Meier Curves coupled with the Cox test was constructed to evaluate survival probability according to the neutralization categories (low, medium, and high) and the total anti-N antibody titers (low and high). ( A ): Kaplan–Meier curve showing the neutralization categories in which patients were classified in their initial measurement and the decrease in survival probability in patients with a negative or low antibody production. ( B ): Kaplan–Meier curve showing the total anti-N production classification (high and low) in which patients were classified in their initial measurement and the decrease in survival probability in patients with a low total anti-N antibody production. ( A ) p = 0.00025, ( B ) p = 0.0359.

    Journal: Vaccines

    Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

    doi: 10.3390/vaccines10122063

    Figure Lengend Snippet: ( A , B ). Antibody titers and survival analysis. Kaplan–Meier Curves coupled with the Cox test was constructed to evaluate survival probability according to the neutralization categories (low, medium, and high) and the total anti-N antibody titers (low and high). ( A ): Kaplan–Meier curve showing the neutralization categories in which patients were classified in their initial measurement and the decrease in survival probability in patients with a negative or low antibody production. ( B ): Kaplan–Meier curve showing the total anti-N production classification (high and low) in which patients were classified in their initial measurement and the decrease in survival probability in patients with a low total anti-N antibody production. ( A ) p = 0.00025, ( B ) p = 0.0359.

    Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

    Techniques: Construct, Neutralization

    Longitudinal measurement of neutralizing antibodies according to viral lineage. Each point represents the median neutralization value with standard error for that follow-up measurement. Wuhan-like lineages are represented by the orange line, the green line represents patients infected with lineage B.1.1.519, the blue line represents patients infected with VOC Delta, and the purple line represents patients infected with Omicron.

    Journal: Vaccines

    Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

    doi: 10.3390/vaccines10122063

    Figure Lengend Snippet: Longitudinal measurement of neutralizing antibodies according to viral lineage. Each point represents the median neutralization value with standard error for that follow-up measurement. Wuhan-like lineages are represented by the orange line, the green line represents patients infected with lineage B.1.1.519, the blue line represents patients infected with VOC Delta, and the purple line represents patients infected with Omicron.

    Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

    Techniques: Neutralization, Infection

    Proportion of patients in each neutralization category barplot collage with four panels, one panel for each of the longitudinal measurements showing the proportion of patients classified according to the following neutralization categories: 0–30% negative production, 31–60% low production, 61–90% medium production, and >90% high production of each viral lineage (Wuhan-WT, B.1.1.519, and VOC Delta). Initial measurement represents a period of <14 days post-symptom onset, follow-up 1 to the period between 14 and 21 days post-symptom onset, follow up-2 to the period between 22 and 30 days post-symptom onset, and follow-up 3 the last measurement (30 days post-symptom onset). * = p < 0.05, *** = p < 0.001.

    Journal: Vaccines

    Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

    doi: 10.3390/vaccines10122063

    Figure Lengend Snippet: Proportion of patients in each neutralization category barplot collage with four panels, one panel for each of the longitudinal measurements showing the proportion of patients classified according to the following neutralization categories: 0–30% negative production, 31–60% low production, 61–90% medium production, and >90% high production of each viral lineage (Wuhan-WT, B.1.1.519, and VOC Delta). Initial measurement represents a period of <14 days post-symptom onset, follow-up 1 to the period between 14 and 21 days post-symptom onset, follow up-2 to the period between 22 and 30 days post-symptom onset, and follow-up 3 the last measurement (30 days post-symptom onset). * = p < 0.05, *** = p < 0.001.

    Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

    Techniques: Neutralization